The short version of Reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-27. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
The half-life, t1/2, is the time taken for the activity of a given amount of a radioactive substance to decay to half of its initial value. The decay constant, λ "lambda", the reciprocal of the mean lifetime (in s−1), sometimes referred to as simply decay rate. The mean lifetime, τ "tau", the average lifetime (1/e life) of a radioactive particle before decay. Although these are constants, they are associated with the statistical behavior of populations of atoms. In consequence, predictions using these constants are less accurate for minuscule samples of atoms. In principle a half-life, a third-life, or even a (1/√2)-life, could be used in exactly the same way as half-life; but the mean life and half-life t1/2 have been adopted as standard times associated with exponential decay. Those parameters can be related to the following time-dependent parameters:
== History == This method was developed by Solomon Berson and Rosalyn Sussman Yalow at the Veterans Administration Hospital in the Bronx, New York. This revolutionary development earned Dr. Yalow the Nobel Prize for Medicine in 1977, the second woman ever to win it. In her acceptance speech, Dr. Yalow said, "The world cannot afford the loss of the talents of half its people if we are to solve the many problems which beset us." Yalow shared the Nobel Prize with Roger Guillemin, and Andrew Schally who earned the prize based on their research into "the peptide hormone production of the brain".
FC Lokomotive Leipzig was promoted to Regionalliga Nordost after finishing Oberliga sixth due to the reserve teams of FC Rot-Weiß Erfurt, Dynamo Dresden, and FC Carl Zeiss Jena being ineligible for promotion. Lokomotive finished in tenth place in the 2012–13 season but were relegated to Oberliga Nordost after finishing 15th in 2013–14. The club stayed in contention for promotion back up to the Regionalliga during the 2014–15 season, having hired former German international Mario Basler as director of sports in early 2015. In the final match of the season, Lok supporters stormed the field after their club had fallen behind 2–0, forcing the match to be abandoned and the club to finish outside of the promotion ranks. The club finished in first place in the southern group of the NOFV-Oberliga and returned to the Regionalliga Nordost for the 2016–17 season.
Sources: en.wikipedia.org
== B == B cell - bacteria - bacterial conjugation - bacterial outer membrane protein - bacterial protein - bacteriorhodopsin - base (chemistry) - base pair - base sequence - basic fibroblast growth factor - Bcl-2 - bcr-abl fusion protein - benzene - benzene ring - beta-2 microglobulin - beta adrenergic receptor - beta sheet - beta-1 adrenergic receptor - beta-2 adrenergic receptor - beta-thromboglobulin - bioaccumulation - biochemistry - biodiversity - bioethics - biogenic amine receptor - bioinformatics - biological membrane - biologist - biology - biomechanics - biomedical model - biomolecule - biophysics - biopolymer - biosalinity - biotechnology - BLAST - blood proteins - boiling point - Boltzmann distribution - Boltzmann principle - bombesin - bombesin receptor - bone morphogenetic protein - bradykinin - bradykinin receptor - BRCA1 - buffer solution
Germany, the birthplace of decaffeinated coffee, is home to several decaffeination plants, including the world's largest, Coffein Compagnie. Over half of the decaf coffee sold in the US first travels from the tropics to Germany for caffeine removal before making its way to American consumers. Coffee manufacturers recover the caffeine and resell it for use in soft drinks and over-the-counter caffeine tablets. The efficiency and selectivity of caffeine removal depend on the decaffeination method used. Water-based processes and supercritical carbon dioxide extraction are generally more selective, as they remove caffeine while preserving a larger proportion of volatile flavor compounds compared to some organic solvent methods. Extraction of caffeine from coffee, to produce caffeine and decaffeinated coffee, can be performed using various solvents. Following are main methods:
Samoyeds can compete in dog agility trials, carting, obedience, showmanship, flyball, tracking, mushing and herding events. Herding instincts and trainability can be measured at non-competitive herding tests. Samoyeds exhibiting basic herding instincts can be trained to compete in herding trials.
Sources: en.wikipedia.org
Not all ECM devices come from the bladder. Extracellular matrix coming from pig small intestine submucosa are being used to repair "atrial septal defects" (ASD), "patent foramen ovale" (PFO) and inguinal hernia. After one year, 95% of the collagen ECM in these patches has been replaced by the body with the normal soft tissue of the heart. Extracellular matrix proteins are commonly used in cell culture systems to maintain stem and precursor cells in an undifferentiated state during cell culture and function to induce differentiation of epithelial, endothelial and smooth muscle cells in vitro. Extracellular matrix proteins can also be used to support 3D cell culture in vitro for modelling tumor development. A class of biomaterials derived from processing human or animal tissues to retain portions of the extracellular matrix are called ECM Biomaterial.
=== Umbilical === Humans and other placental mammals have an umbilical scar (commonly referred to as a belly button or navel) which starts to heal when the umbilical cord is cut after birth. Egg-laying animals have an umbilical scar which, depending on the species, may remain visible for life or disappear within a few days after birth.
== Structure == Glycine, proline, and hydroxyproline must be in their designated positions with the correct configuration. For example, hydroxyproline in the Y position increases the thermal stability of the triple helix, but not when it is located in the X position. The thermal stabilization is also hindered when the hydroxyl group has the wrong configuration. Due to the high abundance of glycine and proline contents, collagen fails to form a regular α-helix and β-sheet structure. Three left-handed helical strands twist to form a right-handed triple helix. A collagen triple helix has 3.3 residues per turn. Each of the three chains is stabilized by the steric repulsion due to the pyrrolidine rings of proline and hydroxyproline residues. The pyrrolidine rings keep out of each other's way when the polypeptide chain assumes this extended helical form, which is much more open than the tightly coiled form of the alpha helix. The three chains are hydrogen bonded to each other. The hydrogen bond donors are the peptide NH groups of glycine residues. The hydrogen bond acceptors are the CO groups of residues on the other chains. The OH group of hydroxyproline does not participate in hydrogen bonding but stabilises the trans isomer of proline by stereoelectronic effects, therefore stabilizing the entire triple helix. The rise of the collagen helix (superhelix) is 2.9 Å (0.29 nm) per residue. The center of the collagen triple helix is very small and hydrophobic, and every third residue of the helix must have contact with the center.
=== Names === Lemborexant is the generic name of the drug and its INNTooltip International Nonproprietary Name while E-2006 was its developmental code name. Lemborexant is sold under the brand name Dayvigo.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.